A 72-week Phase 3 trial (SURMOUNT-1) published in NEJM found tirzepatide 15mg produced mean body weight reduction of 20.9% vs 3.1% placebo, but lean mass accounted for 2540% of total weight lost without metabolic intervention
Suares 2011b
Gastrointestinal adverse events, including nausea, vomiting, constipation, and diarrhea, were the most frequently reported events across treatment groups and were observed most commonly in the liraglutide group
Not approved for diagnostic, therapeutic, or medical applications
It is studied for its potential role in supporting glucose regulation, appetite control, and body composition management through pathways involved in metabolic signaling
If youre basically in good health and already getting an adequate supply of carnitine from the animal protein in your diet, you may feel a slight energy lift, if that, but probably not